Swissmedic Approves Vfmcrp And Caras Kapruvia To Treat Moderate-To-Severe Pruritus Associated With Ckd
Vifor Fresenius Medical Care Renal Pharma (Vfmcrp) And Cara Therapeutics, Inc. Announced That They Have Received Approval For Kapruvia From The Swiss Agency For Therapeutic Products (Swissmedic). Kapruvia Will Be The First Therapy Available For The Treatment Of Moderate-To-Severe Pruritus Associated With Chronic Kidney Disease In Adult Haemodialysis Patients. Swissmedic Approval For Kapruvia Follows Approvals By The Us Food And Drug Administration, By The European Medicines Agency, By The Uk Medicines And Healthcare Products Regulatory Agency, As Well As By Health Canada.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
